Kawasaki disease (KD), a multisystem inflammatory condition observed in younger children, can cause acute vasculitis, most notably affecting the coronary arteries. Currently, KD diagnosis is based on clinical symptoms, including fever for >5 days, bilateral conjunctival injection without exudate, polymorphous exanthema, changes in the lips and mouth (erythema and cracking of lips, strawberry tongue, and diffuse injection of oral and pharyngeal mucosae), changes in the extremities (erythema and edema of the hands and feet), and cervical lymphadenopathy (>1.5 cm in diameter).

Without treatment, approximately 20-25% of children with KD develop coronary artery abnormalities (CAAs). The difficulty of current diagnosis, which based on clinical symptoms established mainly from the epidemiological surveys, in distinguishing Kawasaki disease from other similar diseases’ symptoms consequently delays the timely treatment of children with KD and may increase its risk factors of CAAs.

Our product uses Enzyme-linked immunosorbent assay (hereinafter referred to as ELISA) to measure the biomarkers in the plasma using two specific antibodies (sandwich ELISA). ELISA is the fastest growing and most widely used technology in enzyme immunoassay technology, with highly sensitivity and specificity, easy operation and automation.

The biomarkers can be detected three days after fever in children with Kawasaki disease, and can be distinguished from children with similar disease. Carries out timely and correct clinical diagnosis for medical decision-making. It is the only one in the world that can be used for early In vitro diagnostic reagents for diagnosing KD.